REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due to Alzheimer's Disease)

Last updated: May 19, 2025
Sponsor: Otsuka Pharmaceutical Co., Ltd.
Overall Status: Active - Recruiting

Phase

N/A

Condition

Dementia

Anger

Treatment

Brexpiprazole (Rexulti)

Clinical Study ID

NCT06875986
331-101-00612
  • Ages > 15
  • All Genders

Study Summary

The purpose of this study is to evaluate safety of REXULTI in patients under daily clinical settings. In addition, information on efficacy will be collected.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients diagnosed with Alzheimer's disease

Exclusion

Exclusion Criteria:

Study Design

Total Participants: 200
Treatment Group(s): 1
Primary Treatment: Brexpiprazole (Rexulti)
Phase:
Study Start date:
April 17, 2025
Estimated Completion Date:
September 23, 2028

Connect with a study center

  • Pharmacovigilance Department

    Osaka, 540-0021
    Japan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.